There would be interesting talks.

pubmed.ncbi.nlm.nih.gov/35123128/

It is TM4SF5.

Therapeutic effects of TM4SF5-targeting chimeric and humanized monoclonal antibodies in hepatocellular and colon ca… pubmed.ncbi.nlm.nih.gov/35211652/

Seoul National University College of Pharmacy may open tenure-track faculty positions in this 2022 Spring semester.

Share An Online Entry "Roles of TM4SF5 in Hepatocyte Metabolism" via @EncyclopediaMD1 encyclopedia.pub/entry/25763

Liver‐originated small extracellular vesicles with TM4SF5 target brown adipose tissue for homeostatic glucose clearance onlinelibrary.wiley.com/doi/10.1002/je…

nature.com/articles/s4142…

easlcongress.eu

🟪NEW Article in press❕ #Cirrhosis is associated with lower serological responses to #COVID19 vaccines in patients with #chronicliverdisease 🔓#OpenAccess at👉bit.ly/3TgeZpR #LiverTwitter

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials dlvr.it/SqT4vf

The Novel-Natural-Killer-Cell-Related Gene Signature Predicts the Prognosis and Immune Status of Patients with Hepatocellular Carcinoma dlvr.it/SqTfMc

This study shows how TM4SF5 in hepatocytes initiates metabolic dysfunctiins even by 1~2 week high fat diet, with involving abnormal food intake behaviors and orexigenic apelin expression. sciencedirect.com/science/articl…

We got this out at this happy X-Mas. Glucose‐mediated mitochondrial reprogramming by cholesterol export at TM4SF5‐enriched mitochondria‐lysosome contact sites - Kim - Cancer Communications - Wiley Online Library onlinelibrary.wiley.com/doi/full/10.10…

Have been at Liver Cancer Summit 2024 by EASL. Got heard two talks importatnly supportive for out current projects and ideas with regards to liver disease including HCC/CCA.

제가 어쩌다보니 2026년도 KSMCB (한국분자세포생물학회)의 회장 후보로 추천되어 출마하게 되었습니다. 많은 지원과 소중한 표를 부탁드립니다. 서울대 약학과 이정원

We got this out, which is about a new role of TM4SF5 as an NK cell immune checkpoint, and includes a TM4SF5-specifix Isoxazole small molecules to interrupt the TM4SF5-mediated SLAMF7 downregulation and NK cell immune exhaustion. nature.com/articles/s4139…

Our TM4SF5 story and its therapeutic modalities are going to be exposured both at #BioUSA 2025 and Bio Korea 2025, with being titled as "First-in-class #TM4SF5 inhibitor for MASH (NASH) and HCC Therapy". #BioUSA2025 #immune checkpoint inhibitor